Samsung Biologics, a leading global contract development and manufacturing organization (CDMO), has announced a landmark deal with an Asian pharmaceutical company, securing a $1.24 billion contract for the production of biopharmaceuticals. This agreement marks the largest single client contract for Samsung Biologics, solidifying its position as a major player in the biopharmaceutical manufacturing landscape.
Samsung Biologics, a global contract development and manufacturing organization (CDMO), has announced impressive financial results for the first quarter of fiscal year 2024, driven by the robust demand for its client-centric services and strategic investments in cutting-edge therapeutic technologies. The company reported a 31.3% increase in consolidated revenue and a 26.5% increase in net profit compared to the same period in the previous year.
